Physician profile
Allison Win
NPI 1134367139
$2,385.44
in general payments reported to CMS, 2019-2025
21 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.79 · 2020: $18.79 · 2021: $87.64 · 2022: $443 · 2023: $231 · 2024: $524 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,777.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $383.02 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $354.64 | 2024-2025 | Airsupra, Tezspire, Bevespi Aerosphere |
| Gilead Sciences, INC. | $326.92 | 2021-2022 | |
| Amgen INC. | $193.95 | 2025 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $155.45 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $153.31 | 2019-2025 | Wegovy |
| Astellas Pharma US INC | $147.43 | 2024-2025 | Veozah |
| Abbott Laboratories | $143.48 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $114.73 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $95.57 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $69.81 | 2022-2023 | Vraylar |
| Biohaven Pharmaceuticals, INC. | $39.09 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $33.60 | 2022 | |
| Amarin Pharma, INC. | $29.84 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $28.32 | 2025 | Zoryve |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $23.76 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.85 | 2025 | Jardiance |
| Pfizer INC. | $19.91 | 2024 | |
| Horizon Therapeutics Plc | $18.79 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.29 | 2025 | Xifaxan |
| Ars Pharmaceuticals Operations, INC. | $14.68 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Win listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.